NO20021625L - Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue - Google Patents

Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue

Info

Publication number
NO20021625L
NO20021625L NO20021625A NO20021625A NO20021625L NO 20021625 L NO20021625 L NO 20021625L NO 20021625 A NO20021625 A NO 20021625A NO 20021625 A NO20021625 A NO 20021625A NO 20021625 L NO20021625 L NO 20021625L
Authority
NO
Norway
Prior art keywords
receptor antagonist
synergistic combinations
gaba
structural analogue
gaba structural
Prior art date
Application number
NO20021625A
Other languages
Norwegian (no)
Other versions
NO20021625D0 (en
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20021625L publication Critical patent/NO20021625L/en
Publication of NO20021625D0 publication Critical patent/NO20021625D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer metoder for behandling ved anvendelse av synergistiske kombinasjoner av en NKi-reseptor-antagonist og en GABA-analog og farmasøytiske preparater og produkter inneholdende NKrreseptorantagonisten og GABA-analogen. Foreliggende oppfinnelse tilveiebringer også anvendelse av en NKi-reseptorantagonist og en GABA- analog for fremstilling av et medikament for behandling eller forhindring av kronisk smerte.The present invention provides methods of treatment using synergistic combinations of an NK 1 receptor antagonist and a GABA analog and pharmaceutical compositions and products containing the NK 1 receptor antagonist and GABA analog. The present invention also provides the use of an NK 1 receptor antagonist and a GABA analogue for the manufacture of a medicament for the treatment or prevention of chronic pain.

NO20021625A 1999-10-07 2002-04-05 Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue NO20021625D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (2)

Publication Number Publication Date
NO20021625L true NO20021625L (en) 2002-04-05
NO20021625D0 NO20021625D0 (en) 2002-04-05

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021625A NO20021625D0 (en) 1999-10-07 2002-04-05 Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue

Country Status (38)

Country Link
EP (2) EP1221950B1 (en)
JP (2) JP2003510356A (en)
KR (1) KR20020060192A (en)
CN (1) CN1387434A (en)
AP (1) AP2002002501A0 (en)
AR (1) AR029646A1 (en)
AT (1) ATE269072T1 (en)
AU (2) AU7663300A (en)
BG (1) BG106548A (en)
BR (1) BR0014598A (en)
CA (1) CA2385930A1 (en)
CO (1) CO5280195A1 (en)
CR (1) CR6614A (en)
CZ (1) CZ20021116A3 (en)
DE (1) DE60011650T2 (en)
DK (1) DK1221950T3 (en)
EA (1) EA004266B1 (en)
EE (1) EE200200185A (en)
ES (1) ES2220542T3 (en)
GT (1) GT200000166A (en)
HR (1) HRP20020286A2 (en)
HU (1) HUP0203466A3 (en)
IL (1) IL148965A0 (en)
IS (1) IS6318A (en)
MA (1) MA26826A1 (en)
MX (1) MXPA02003484A (en)
NO (1) NO20021625D0 (en)
NZ (1) NZ517949A (en)
OA (1) OA12063A (en)
PA (1) PA8504301A1 (en)
PE (1) PE20010708A1 (en)
PL (1) PL357498A1 (en)
PT (1) PT1221950E (en)
SK (1) SK4542002A3 (en)
TR (1) TR200200913T2 (en)
UY (1) UY26376A1 (en)
WO (2) WO2001024792A1 (en)
ZA (1) ZA200202675B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (en) * 2002-04-24 2005-08-31 柏树生物科学公司 Prevention and treatment of functional somatic disorders, including stress-related disorders
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1492519B1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (en) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilized pharmaceutical composition containing pregabalin
MX2013000946A (en) 2010-07-30 2013-02-27 Toray Industries Therapeutic agent or prophylactic agent for neuropathic pain.
EP3753410A3 (en) * 2010-09-28 2021-04-28 The Regents Of The University Of California Combinations comprising gaba agonists in treatment of hyperglycemia
ES3064256T3 (en) * 2019-03-26 2026-04-23 Orion Corp Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (en) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon CNS PENETRATING NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSIVE AND / OR ANXIOLYTIC
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
HRP20020286A2 (en) 2003-08-31
PT1221950E (en) 2004-08-31
GT200000166A (en) 2002-03-30
CN1387434A (en) 2002-12-25
CA2385930A1 (en) 2001-04-12
CO5280195A1 (en) 2003-05-30
JP2003510356A (en) 2003-03-18
WO2001024791A1 (en) 2001-04-12
JP2003510355A (en) 2003-03-18
WO2001024792A9 (en) 2002-09-06
SK4542002A3 (en) 2003-09-11
AU7663300A (en) 2001-05-10
TR200200913T2 (en) 2002-09-23
UY26376A1 (en) 2000-12-29
WO2001024792A1 (en) 2001-04-12
IL148965A0 (en) 2002-11-10
BG106548A (en) 2002-12-29
AR029646A1 (en) 2003-07-10
DE60011650T2 (en) 2005-07-14
PE20010708A1 (en) 2001-07-27
EE200200185A (en) 2003-04-15
ZA200202675B (en) 2003-04-15
AU1696201A (en) 2001-05-10
EP1221950B1 (en) 2004-06-16
EP1221950A1 (en) 2002-07-17
NZ517949A (en) 2003-08-29
EP1233766A1 (en) 2002-08-28
HUP0203466A3 (en) 2005-03-29
OA12063A (en) 2006-05-03
NO20021625D0 (en) 2002-04-05
AP2002002501A0 (en) 2002-06-30
IS6318A (en) 2002-03-21
MXPA02003484A (en) 2004-09-10
DK1221950T3 (en) 2004-09-20
ATE269072T1 (en) 2004-07-15
HUP0203466A2 (en) 2003-02-28
CZ20021116A3 (en) 2003-05-14
DE60011650D1 (en) 2004-07-22
EA004266B1 (en) 2004-02-26
KR20020060192A (en) 2002-07-16
CR6614A (en) 2003-12-04
PA8504301A1 (en) 2002-08-26
ES2220542T3 (en) 2004-12-16
BR0014598A (en) 2002-06-11
MA26826A1 (en) 2004-12-20
EA200200303A1 (en) 2002-08-29
PL357498A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
DE4497905T1 (en) Pharmaceutical composition for the prevention and treatment of motion sickness syndrome
ATE418986T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WHICH CONTAIN A NICOTINE ANALOG AND AN ACETYLCHOLINESTERASE INHIBITOR
IS8807A (en) Use of daptomycin and the pharmaceutical compositions containing it
MX9602818A (en) A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
ATE265857T1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE PREVENTION OR TREATMENT OF HYPEROXALUria
ATE334668T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES
BR9709915A (en) Compound pharmaceutical composition use of the compound and processes for the treatment or prevention of physiological disorders associated with an excess of tachykinins and for the preparation of the compound
DE69805973D1 (en) TREATING HEART CRYSTAL DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM / CALMODULIN-DEPENDENT PROTEIN KINASE
ZA943744B (en) Therapeutic substituted guanidines
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
MXPA94009086A (en) Therapeutic substituted guanidines.
EP0657167A3 (en) Use of oenotheine B for the manufacture of a medicament for the treatment of disorders related to hyperandrogenism, pharmaceutical compositions containing oenotheine B and a process for its preparation from epilobium parviflorum.
DE69420229D1 (en) Pharmaceutical composition for the treatment of AIDS
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DE69822810D1 (en) SOMATOSTATIN AND SOMATOSTATIN AGONISTE FOR THE TREATMENT OF INSULIN SENSITIVITY AND SYNDROME X
EP0744176A3 (en) Methods for inhibiting bone loss
BR9812531A (en) Combination of components, pharmaceutical preparation, production thereof, and use of the combination or pharmaceutical preparation
HUP0000110A2 (en) Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain
BR0015781A (en) Pharmaceutical composition for treatment of diseases associated with decreased bone mass
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
EP0564216A3 (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application